Abbott

34,735.00
-685.00
(-1.93%)
Market Cap
75,265.00 Cr
EPS
665.62
PE Ratio
52.20
Dividend Yield
1.37 %
Industry
Healthcare
52 Week High
37,000.00
52 Week Low
25,325.00
PB Ratio
17.44
Debt to Equity
0.03
Add Ratio
hide

Investment Returns

In Long Term
In Short Term
1 Year
0.00%
2 Years
0.00%
3 Years
0.00%
4 Years
0.00%
5 Years
0.00%
Analyst Rating
- By Refinitiv from6 analysts
BUY
Analysts have suggested that investors can buy this stock
Buy
Buy+100.00 %
+100.00 %
Hold
Hold0.0 %
0.0 %
Sell
Sell0.0 %
0.0 %
Competitors
LTP
Market Cap (₹ Cr.)
P/E Ratio
Revenue (₹ Cr.)
YoY Revenue Growth %
Net Profit (₹ Cr.)
YoY Profit Growth %
RSI
1,676.30
#1 4,03,016.30
35.07
#1 52,041.20
12.06
#1 10,980
-18.99
48.33
6,906.50
1,82,536.20
83.65
9,360.00
0.89
2,117
23.05
68.54
1,513.30
1,21,858.90
23.76
28,409.50
7.12
5,291
30.28
54.26
3,368.00
1,12,841.10
59.12
11,317.00
11.59
2,054
10.91
62.08
1,307.40
1,07,768.20
#1 19.63
33,741.20
12.36
5,725
21.14
54.13
1,001.00
1,00,563.00
21.57
22,573.80
13.82
3,977
-0.19
69.99
2,439.50
97,474.10
50.68
12,207.40
19.57
1,925
-10.91
59.65
1,980.90
89,274.80
27.51
22,192.10
#1 19.94
3,024
#1 112.49
53.08
34,735.00
#9 75,265.00
#8 52.20
#10 6,409.15
#8 10.80
#10 1,417
#3 27.83
64.97
1,191.30
67,146.50
20.01
31,378.10
17.55
3,366
-0.50
63.70

Automatic Screeners on ScanX

Forecast
Actual
Growth Rate
Revenue Growth
10.80 %
Net Income Growth
26.52 %
Cash Flow Change
35.75 %
ROE
9.07 %
ROCE
9.92 %
EBITDA Margin (Avg.)
12.91 %

Balance Sheet

Balance Sheet
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Total Assets
1,374
1,617
2,066
2,416
2,941
3,547
3,840
4,224
4,556
5,194
5,917
Fixed Assets
96
109
110
81
105
270
251
271
237
225
354
Current Assets
1,226
1,451
1,893
2,266
2,761
3,205
3,487
3,853
3,025
3,246
4,765
Capital Work in Progress
4
3
6
2
1
2
1
1
4
10
18
Investments
0
0
0
0
0
0
0
0
0
0
882
Other Assets
1,274
1,505
1,950
2,333
2,835
3,275
3,589
3,953
4,315
4,958
0
Total Liabilities
1,374
1,617
2,066
2,416
2,941
3,547
3,840
4,224
4,556
5,194
5,917
Current Liabilities
397
382
632
668
857
891
1,031
1,203
1,206
1,343
1,407
Non Current Liabilities
39
39
47
55
75
224
207
201
161
152
277
Total Equity
938
1,196
1,387
1,693
2,009
2,432
2,602
2,820
3,189
3,699
4,233
Reserve & Surplus
916
1,174
1,366
1,672
1,987
2,410
2,581
2,799
3,167
3,678
4,212
Share Capital
21
21
21
21
21
21
21
21
21
21
21

Cash Flow

Cash Flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
Net Cash Flow
-30
91
62
-165
99
8
73
-86
107
52
Investing Activities
-187
-77
-155
-215
-257
-401
-72
-396
-148
-416
Operating Activities
215
249
307
153
499
626
727
948
893
1,213
Financing Activities
-58
-80
-90
-102
-143
-217
-582
-637
-639
-745

Share Holding

% Holding
Mar 2021
Jun 2021
Sept 2021
Dec 2021
Mar 2022
Jun 2022
Sept 2022
Dec 2022
Mar 2023
Jun 2023
Sept 2023
Dec 2023
Mar 2024
Jun 2024
Sept 2024
Dec 2024
Mar 2025
Promoter
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
74.99 %
FIIs
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.18 %
0.18 %
0.18 %
0.16 %
0.16 %
0.16 %
DIIs
4.60 %
5.80 %
4.30 %
4.20 %
4.96 %
5.24 %
7.73 %
8.39 %
8.62 %
8.67 %
8.71 %
8.74 %
8.91 %
8.81 %
8.99 %
9.01 %
8.92 %
Government
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
0.00 %
Public / Retail
16.15 %
15.83 %
15.60 %
15.81 %
15.15 %
14.72 %
14.60 %
14.25 %
14.07 %
13.95 %
13.89 %
13.97 %
13.80 %
13.86 %
13.65 %
13.59 %
13.66 %
Others
4.26 %
3.38 %
5.11 %
5.01 %
4.91 %
5.06 %
2.68 %
2.37 %
2.32 %
2.39 %
2.42 %
2.13 %
2.12 %
2.16 %
2.21 %
2.25 %
2.28 %
No of Share Holders
0
84,478
75,540
73,417
83,236
90,567
82,113
83,526
72,086
69,582
68,885
72,252
69,382
71,588
69,449
67,892
69,934

Dividend History

Dividends per share (FY)
Dividend yield (FY) %
Dividends per share (FY)
Dividend yield (FY) %
Annual Cash Flows 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Dividend Per Share (₹) 0.00 40 55 65 250 275 275 325 410 0.00
Dividend Yield (%) 0.00 0.73 0.75 0.42 1.67 1.55 1.26 1.2 1.33 0.00

Corporate Action

Record Date Corporate Action Information Announcement Day LTP at Annoucement LTP at Record Day
13 Aug 2025 ANNUAL GENERAL MEETING Annual General Meeting
NA
13 Aug 2025 30,330.00 34,735.00
25 Jul 2025 DIVIDEND Dividend
₹ 475.00 /share
25 Jul 2025 30,330.00 34,735.00
15 May 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
15 May 2025 30,345.00 30,330.00
05 Feb 2025 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
05 Feb 2025 25,745.95 27,802.10
07 Nov 2024 QUARTERLY RESULT ANNOUNCEMENT Quarterly Result Announcement
NA
07 Nov 2024 28,433.45 28,314.00
08 Aug 2024 ANNUAL GENERAL MEETING Annual General Meeting
NA
08 Aug 2024 25,562.40 27,223.00
19 Jul 2024 DIVIDEND Dividend
₹ 410.00 /share
19 Jul 2024 25,562.40 27,407.65
21 Jul 2023 DIVIDEND Dividend
₹ 145.00 /share
21 Jul 2023 20,884.85 23,187.15
21 Jul 2023 DIVIDEND Dividend
₹ 180.00 /share
21 Jul 2023 20,884.85 23,187.15
04 Aug 2022 DIVIDEND Dividend
₹ 130.00 /share
02 Aug 2022 17,636.10 20,420.95
04 Aug 2022 DIVIDEND Dividend
₹ 145.00 /share
02 Aug 2022 17,636.10 20,420.95
21 Jul 2021 DIVIDEND Dividend
₹ 155.00 /share
19 Jul 2021 16,053.85 17,427.95
21 Jul 2021 DIVIDEND Dividend
₹ 120.00 /share
19 Jul 2021 16,053.85 17,427.95

Announcements

Closure of Trading Window8 days ago
Communication To Shareholders : Intimation About Tax Deduction At Source On Dividend.Jun 18, 2025
Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 19, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 16, 2025
Record Date For Entitlement Of DividendMay 15, 2025
Annual General Meeting On August 13 2025May 15, 2025
Announcement under Regulation 30 (LODR)-Dividend UpdatesMay 15, 2025
Results For The Financial Year Ended March 31 2025May 15, 2025
Board Meeting Outcome for Outcome Of Board MeetingMay 15, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMay 07, 2025
Board Meeting Intimation for Intimation Under Regulation 29 (1) (A) And (E) Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.May 07, 2025
Announcement Under Regulation 30.Apr 30, 2025
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure AApr 24, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 18, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 16, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 16, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 10, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementApr 01, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementMar 26, 2025
Closure of Trading WindowMar 25, 2025
Rumour verification - Regulation 30(11)Mar 06, 2025
Announcement Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.Feb 27, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 20, 2025
Integrated Filing (Financial)Feb 06, 2025
Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 06, 2025
Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2024Feb 05, 2025
Board Meeting Outcome for Outcome Of Board MeetingFeb 05, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementFeb 03, 2025
Board Meeting Intimation for Intimation Of Board Meeting Scheduled On February 5 2025 For Considering Unaudited Financial Results For Quarter And Nine Months Ended December 31 2024.Jan 28, 2025
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations 2015.Jan 23, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJan 21, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJan 16, 2025
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 09, 2025
Announcement under Regulation 30 (LODR)-Change in ManagementJan 03, 2025
Closure of Trading WindowDec 23, 2024
Announcement under Regulation 30 (LODR)-Resignation of DirectorDec 16, 2024
Announcement under Regulation 30 (LODR)-Resignation of Chief Financial Officer (CFO)Dec 16, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateDec 13, 2024
Abbott Launches 14 Valent Pneumococcal Conjugate Vaccine (PCV-14) That Offers Broadest Protection For Children Against Pneumococcal Bacterial Infections.Nov 28, 2024
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements), Regulations, 2015.Nov 28, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 14, 2024
Intimation Under Regulation 30 Of The Securities And Exchange Board Of India ( Listing Obligations And Disclosure Requirements), Regulations, 2015.Nov 14, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 12, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 08, 2024
Announcement under Regulation 30 (LODR)-Newspaper PublicationNov 08, 2024
Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate CertificateNov 07, 2024
Related Party Transaction Statement For The Half Year Ended September 30, 2024Nov 07, 2024
Announcement under Regulation 30 (LODR)-Change in DirectorateNov 07, 2024
Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2024Nov 07, 2024
Board Meeting Outcome for Outcome Of Board MeetingNov 07, 2024

Technical Indicators

RSI(14)
Neutral
64.97
ATR(14)
Less Volatile
1,045.94
STOCH(9,6)
Neutral
70.35
STOCH RSI(14)
Neutral
67.42
MACD(12,26)
Bullish
313.11
ADX(14)
Strong Trend
31.94
UO(9)
Bearish
56.07
ROC(12)
Uptrend And Accelerating
10.04
WillR(14)
Neutral
-35.45

Mutual Fund Holdings

Funding HouseCurrent Holding %1M Change1M Change %3M Change %Last 6M Trend
Nippon India Pharma Fund Direct-Growth
2.87%
-10206
-0.36%
-0.59%
SBI MNC Direct Plan-Growth
4.31%
-10000
-0.59%
-0.83%
Edelweiss Business Cycle Fund Direct-Growth
1.39%
8402
1.39%
1.39%
360 ONE Quant Fund Direct - Growth
2.90%
6752
2.90%
2.90%
WhiteOak Capital Mid Cap Fund Direct - Growth
1.37%
3420
0.25%
0.26%
SBI Quant Fund Direct-Growth
1.09%
2376
0.19%
0.31%
Bajaj Finserv Large and Mid Cap Fund Direct-Growth
1.31%
-1622
-0.32%
-0.46%
Nippon India Retirement Fund - Wealth Creation Scheme Direct-Growth
0.76%
-1000
-0.11%
-0.15%
Union Midcap Fund Direct - Growth
1.47%
917
0.12%
-0.22%
Shriram Multi Sector Rotation Fund Direct-Growth
0.00%
-900
-1.39%
0.00%
Shriram Flexi Cap Fund Direct - Growth
0.00%
-800
-1.79%
-1.85%
Samco Multi Cap Fund Direct-Growth
1.56%
759
0.59%
0.89%
WhiteOak Capital Multi Cap Fund Direct - Growth
0.57%
573
0.05%
0.12%
WhiteOak Capital Large & Mid Cap Fund Direct - Growth
0.74%
523
0.07%
0.08%
Bajaj Finserv Healthcare Fund Direct-Growth
2.33%
498
0.44%
0.38%
Samco Multi Asset Allocation Fund Direct-Growth
1.73%
362
0.31%
1.73%
WhiteOak Capital Quality Equity Fund Direct-Growth
1.80%
344
0.03%
-0.16%
Shriram Multi Asset Allocation Fund Direct - Growth
0.00%
-300
-0.61%
0.00%
Shriram ELSS Tax Saver Fund Direct - Growth
0.00%
-300
-1.87%
-1.92%
Samco Dynamic Asset Allocation Fund Direct - Growth
0.60%
291
0.23%
0.60%
WhiteOak Capital ELSS Tax Saver Fund Direct - Growth
0.53%
238
0.17%
0.14%
Shriram Aggressive Hybrid Fund Direct -Growth
0.00%
-200
-1.27%
0.00%
ITI Mid Cap Fund Direct - Growth
0.77%
185
0.01%
0.77%
WhiteOak Capital Pharma and Healthcare Fund Direct - Growth
2.25%
104
0.05%
0.28%
NJ Flexi Cap Fund Direct - Growth
0.46%
88
0.00%
-0.04%

About Abbott

Abbott India Ltd is a leading multinational pharmaceutical company in India. It operates an owned manufacturing facility in Goa and works with various independent contract manufacturers across the country. The company sells its products primarily within India through independent distributors. Abbott India provides pharmaceutical products and solutions across various therapeutic areas including Women's Health, Gastroenterology, Central Nervous System, Metabolics, Multi-Specialty, Vaccines, and Consumer Health. The company is structured into four divisions: Primary Care, Specialty Care-Methabolics and Urology, Specialty Care-Neuroscience, and Hospital Care. Abbott India manufactures and markets a wide range of products including Brufen, Prothiaden, Thyronorm, Leptos, Digene, Cremaffin, Influvac, and many others. The company has expanded its product portfolio through launches, acquisitions, and partnerships over the years. Abbott India is engaged in research and development, conducting clinical studies and publishing in medical journals. The company has also been recognized for innovation in the pharmaceutical industry.
Chairperson NameMunir Shaikh